CTAD and ADDF Join Forces to Launch Biotech Showcase at CTAD 2026, Aiming to Accelerate Next-Generation Alzheimer's Therapies
核心洞察
The Clinical Trials on Alzheimer's Disease (搜索) (CTAD) conference and the Alzheimer's Drug Discovery Foundation (搜索) (ADDF) announced a collaboration on CTAD's annual Biotech Showcase to spotlight emerging biotech companies developing novel Alzheimer's therapeutics, diagnostics, and technologies.
The initiative aims to connect promising biotechnology companies with investors, industry leaders, and clinical trial experts to accelerate translation of scientific discoveries into patient-ready treatments.
ADDF CEO Isobel Coleman emphasized that AI is beginning to reshape how new therapies are identified and evaluated, and the Alzheimer's pipeline looks meaningfully different than it did five years ago.
The Clinical Trials on Alzheimer's Disease (搜索) (CTAD) conference and the Alzheimer's Drug Discovery Foundation (搜索) (ADDF) announced on June 16, 2026, that they will collaborate on CTAD's annual Biotech Showcase, a strategic initiative designed to accelerate the development of next-generation therapeutics, diagnostics, and technologies for Alzheimer's disease and related dementias. The partnership brings together CTAD's deep expertise in clinical trials with the ADDF's established ability to convene scientists, investors, pharmaceutical leaders, and philanthropists.
"This is a moment of incredible progress and rapid diversification for the Alzheimer's field," said Isobel Coleman, Chief Executive Officer of the ADDF. "Our understanding of disease mechanisms is deepening, AI is beginning to reshape how we identify and evaluate new therapies, and the pipeline looks meaningfully different than it did five years ago. The opportunity now is to match that scientific momentum with the investment and collaboration the field needs, and that is exactly what this showcase will do: pair scientific innovation with the capital and collaboration needed to move discoveries from the lab to patients."
The Biotech Showcase will feature selected companies presenting their science and development programs to industry leaders, investors, and other key decision-makers actively engaged in the Alzheimer's field. Participating companies will deliver three-minute lightning talks, participate in live Q&A sessions, receive real-time feedback from Alzheimer's clinical researchers and industry leaders, and connect directly with investors and decision-makers.
Jacques Touchon, MD, PhD, Co-Founder and Co-Chairman of CTAD, underscored the importance of rigorous clinical development in the current landscape. "The progress we are seeing across the Alzheimer's pipeline makes rigorous clinical development more important than ever," said Touchon. "As the field moves toward more targeted and ultimately more personalized approaches, it is critical that we help advance this momentum by creating the partnerships and networks needed to translate emerging science into meaningful progress."
The session is structured to provide expert feedback, increase visibility for emerging companies, and create high-value connections that can help promising programs advance through clinical development. The second submission cycle for abstracts will open on September 3, 2026.
The 19th CTAD conference will convene in Boston, USA, on November 16–19, 2026. Since its founding in 2008, CTAD has grown into the premier global forum dedicated exclusively to Alzheimer's disease (搜索) clinical research, bringing together investigators, clinicians, industry scientists, and regulatory experts. A distinguishing feature of CTAD is its single plenary setting, ensuring that every participant shares the same scientific conversations regardless of background or affiliation. CTAD serves as the official conference of the Journal of Prevention of Alzheimer's Disease (JPAD), which holds a 2024 Impact Factor of 7.8.
The ADDF, founded in 1998 by Leonard A. and Ronald S. Lauder, is the only public charity solely focused on funding drug development for Alzheimer's disease (搜索). Employing a venture philanthropy model, the foundation has played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD (搜索)®) to market. Through donor generosity, the ADDF has awarded nearly $400 million to fund 792 Alzheimer's drug development, biomarker, and prevention programs across 21 countries.